Terri Parker, MD

Hematology & Oncology, Hematologic Oncology

Telehealth is available

Learn more about telehealth

Patient type treated

Adult

Accepting new patients

Yes

Referral required

From patients or physicians

Insurance accepted

Biography

Dr. Parker's role includes caring for patients with malignant hematological conditions in the ambulatory setting as well as on the inpatient and consultative hematology services. Her active research interest is in plasma cell disorders including multiple myeloma and AL amyloidosis.

Learn more about Dr. Parker>>

Titles

Assistant Professor of Medicine (Hematology)
Assistant Medical Director, Smilow Cancer Hospital Care Center, North Haven

Education & Training

Fellowship
Yale University School of Medicine (2012)
Fellowship
University of Connecticut Health Center (2009)
Residency
University of Connecticut Health Center (2008)
MD
St. George's University School of Medicine Grenada (2005)
BS
University of Pittsburgh (2001)

Additional Information

Publications

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, Dingli D, Cornell RF, Hofmeister CC, Siegel D, Berdeja JG, Reece D, White D, Lentzsch S, Gasparetto C, Huff CA, Jagannath S, Baz R, Nooka AK, Richter J, Abonour R, Parker TL, Yee AJ, Moreau P, Lonial S, Tuchman S, Weisel KC, Mohty M, Choquet S, Unger TJ, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman MG, Dimopoulos MA. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia 2020, 34:2430-2440.
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet. Oncology 2020, 21:1317-1330.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. The New England Journal Of Medicine 2019, 381:727-738.
A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM, Parker T. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma. The Oncologist 2018, 23:397-e30.
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36:859-866.
Antigen-mediated regulation in monoclonal gammopathies and myeloma.
Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV. Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight 2018, 3.
Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial.
Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV. Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. Clinical Lymphoma, Myeloma & Leukemia 2017, 17:296-304.e2.
Management of isolated calf vein thrombosis in cancer patients.
Brahmandam AS, Brownson K, Skrip L, Parker T, Indes J, Sarac T, Dardik A, Chaar CI. Management of isolated calf vein thrombosis in cancer patients. Vascular 2016, 24:64-9.
Previously undiagnosed fatal familial haemophagocytic lymphohistiocytosis in a 24-year-old woman.
Barmettler S, Nowak RJ, Parker T, Price C. Previously undiagnosed fatal familial haemophagocytic lymphohistiocytosis in a 24-year-old woman. BMJ Case Reports 2016, 2016.
Leukaemic vasculitis with myelodysplastic syndrome.
Odell ID, Zeidan AM, Parker TL, Colegio OR, Subtil A. Leukaemic vasculitis with myelodysplastic syndrome. Lancet 2015, 386:501-2.
Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart.
Bar N, Parker TL, Dhodapkar MV. Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33:3689-90.
Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant.
Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplantation 2013, 48:646-50.
Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.
Parker T, Barbarotta L, Foss F. Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma. Future Oncology (London, England) 2013, 9:21-9.
Chronic lymphocytic leukemia: prognostic factors and impact on treatment.
Parker TL, Strout MP. Chronic lymphocytic leukemia: prognostic factors and impact on treatment. Discovery Medicine 2011, 11:115-23.

Patient Care Organizations